# Zolacabtagene autoleucel PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zolacabtagene-autoleucel

> The next catalyst for zolacabtagene autoleucel, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is its topline data readout, May to Aug 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | zolacabtagene autoleucel |
| Codes | BMS-986353, CC-97540 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | Chronic Immune Thrombocytopenia |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May to Aug 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Immune Thrombocytopenia; Autoimmune Hemolytic Anemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07603557 (Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-05-06 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." https://clinicaltrials.gov/study/NCT07603557

### May 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Immune Thrombocytopenia; Autoimmune Hemolytic Anemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07603557 (Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-05-06 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." https://clinicaltrials.gov/study/NCT07603557

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zolacabtagene-autoleucel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zolacabtagene autoleucel PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zolacabtagene-autoleucel

```bibtex
@misc{secapidev_pdufa_zolacabtagene_autoleucel_20261116,
  title        = {Zolacabtagene autoleucel PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zolacabtagene-autoleucel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zolacabtagene_autoleucel_20261116","title":"Zolacabtagene autoleucel PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zolacabtagene-autoleucel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
